Search

Your search keyword '"Roodt, Jan"' showing total 39 results
Start Over Author "Roodt, Jan"
39 results on '"Roodt, Jan"'

24. Student-Centered Learning and Agency in Unprecedented Times.

Author

Grant, Ginger, Dinevski, Dianna, Roodt, Jan Hendrik, Henry, Steve, Iskov, Thomas, and Tange, Niels Bjerre

Abstract

We were invited during May 2021 to join a small and focussed group of researchers working in the student-centered learning (SCL) space. The aim of our agreement was to open up opportunities for collaborative studies for students and staff. The idea was, at the time, that people would have the opportunity to visit physically and interact with like- minded learners and professional staff around matters of mutual interest in the practice-based and work-based education environment. During the COVID pandemic, other ways had to be found to work around the restrictions on travel and interaction. The invitation for collaboration involved three separate institutions from three countries and the call was to initiate our research based on the question: How can we move toward a joint research agenda for delivering professional practice programmes on the basis of the SCLT- review that makes sense both from a comparative perspective and from three, individual, institutional viewpoints? This is our story. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

28. Coronary artery in-stent stenosis persists despite inhibition of the von Willebrand factor - collagen interaction in baboons

Author

Badenhorst, Philip, primary, Pieters, Henry, primary, Lamprecht, Seb, primary, Roodt, Jan, primary, Janssens, Stefan, primary, Meiring, Muriel, primary, Vanhoorelbeke, Karen, primary, Bruwer, André, primary, Brown, Stephen, primary, De Meyer, Simon, additional, Staelens, Stephanie, additional, and Deckmyn, Hans, additional

Published
2007
Full Text
View/download PDF

29. The Cape Chacma baboon is not suitable for evaluating human targeted anti-GPVI agents.

Author

Janse van Rensburg, Walter J., Badenhorst, Philip N., and Roodt, Jan P.

Subjects
PLATELET aggregation inhibitors, CHACMA baboon, TARGETED drug delivery, DRUG efficacy, MEDICATION safety, ACUTE coronary syndrome, TREATMENT of acute coronary syndrome, PATIENTS
Abstract

An effective and safe anti-platelet drug is central to the management of patients with acute coronary syndrome (ACS). Glycoprotein VI (GPVI) is currently regarded as a potential target for novel anti-platelet agents due to its collagen-binding potential. Development of anti-thrombotics is associated with testing in animals. We have previously successfully evaluated anti-platelet drugs in the Cape Chacma baboon (Papio ursinus). However, various anti-GPVI agents did not have an effect on baboons when evaluated in our arterial thrombosis model. To evaluate the suitability of baboons for GPVI studies, we performed collagen-induced platelet aggregation, GPVI quantification and DNA sequencing. Baboon platelets needed double the amount of collagen compared to human platelets to illicit proper aggregation. GPVI quantification was unsuccessful due to non-binding of monoclonal antibodies. Sequencing of the GPVI gene revealed 36 SNPs leading to 14 amino acid changes, as well as a 9 bp deletion causing a 3 amino acid deletion. Several of the amino acid changes were within the ligand binding region of GPVI, causing limited binding of humanized anti-GPVI antibodies to the baboon platelets. Therefore, the baboon was deemed not suitable to evaluate human targeted anti-GPVI agents. [ABSTRACT FROM PUBLISHER]

Published
2015
Full Text
View/download PDF

30. ALX-0081 Nanobody™, an Engineered Bivalent Anti-Thrombotic Drug Candidate with Improved Efficacy and Safety as Compared to the Marketed Drugs.

Author

Silence, Karen, primary, Jonckheere, Heidi, additional, Casteels, Peter, additional, Roodt, Jan, additional, Meiring, Muriel, additional, Lamprecht, Seb, additional, IJsseldijk, Martin, additional, de Smet, Kristi, additional, van der Jeugt, Bob, additional, de Groot, Flip, additional, and Dreier, Torsten, additional

Published
2006
Full Text
View/download PDF

33. The Determination of the Inhibitory Activity of Some Factor VIII Type II Inhibitor Antibodies Is Biased by the Type of Factor VIII Assay.

Author

Jacquemin, Marc G., primary, Lamprecht, Seb, primary, Lavend’homme, Renaud, primary, Roodt, Jan, primary, Chatelain, Bernard, primary, Deneys, Veronique, primary, Dewaele, Jeroen, primary, Stassen, Jean-Marie, primary, Meiring, Muriel, primary, Saint-Remy, Jean Marie, primary, Pieters, Henry, primary, and Badenhorst, Philip, primary

Published
2005
Full Text
View/download PDF

37. Tirofiban versus abciximab: tirofiban is administered at suboptimal dosages when evaluated in an arterial thrombosis model in non-human primates.

Author

Rensburg, Walter, Roodt, Jan, Lamprecht, Seb, Meiring, S., and Badenhorst, Philip

Subjects
TIROFIBAN, ABCIXIMAB (Drug), DRUG dosage, ARTERIAL occlusions, THROMBOSIS, PRIMATES as laboratory animals
Abstract

To prevent thrombosis in high-risk acute coronary syndrome patients undergoing percutaneous coronary intervention for re-vascularisation, concomitant administration of a glycoprotein IIb/IIIa inhibitor, such as abciximab, tirofiban or eptifibatide, is recommended. Abciximab and eptifibatide are mostly preferred over tirofiban, which is less effective in preventing ischaemic events. We compared the efficacy and bleeding potential of escalating doses of tirofiban and abciximab in non-human primates. The efficacy of tirofiban and abciximab in inhibiting cyclic flow reductions (CFRs) was tested in a high shear arterial thrombosis model. Bleeding was evaluated with the template bleeding time and an incision bleeding model. Abciximab completely inhibited arterial thrombosis after injection of its therapeutic bolus dose. With tirofiban, a dose three times higher than the recommended therapeutic dose caused weak inhibition characterised by a return of CFRs after re-injury. At nine times the recommended therapeutic dose, complete inhibition was observed, and the efficacy of tirofiban was comparable to abciximab at its therapeutic bolus dose. Blood loss was less than with abciximab at its effective dose. In this model, tirofiban compared favourably with abciximab, although only at a dose of 3-9 times the therapeutic dose, and caused less bleeding than abciximab. [ABSTRACT FROM AUTHOR]

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results